Quarterly report · Q1
2503.TEDINET S100TE18
Period2024-01-01 → 2024-03-31
Filed2024-05-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥501.8bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.13T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥450.3bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥30.8bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥11.0bn | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥44.2bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥197.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.1bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥25.9bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥112.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥5.6bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥32.6bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥11.3bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.00T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥2.87T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.47T | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.55T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.44T | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.46T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.43T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.23T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.25T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.16T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.13T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥971.9bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥151.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥131.4bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥116.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥88.1bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥39.9bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥203.2bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥41.9bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥65.3bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥226.1bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥31.4bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥34.7bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥35.9bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥8.6bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥31.98 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥139.16 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥6.9 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥31.98 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥139.15 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥6.9 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 38.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.5% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-03-31 | ¥20.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥15.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-03-31 | −¥158m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-03-31 | −¥17.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-03-31 | −¥17.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-03-31 | −¥12.3bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥238.6bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥238.2bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥379m |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥18.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥32.7bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥31.9bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥726m |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥1.7bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥122.2bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥121.5bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥645m |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥12.2bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥105.6bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥105.5bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥67m |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥16.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-03-31 | ¥22.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-03-31 | ¥6.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥16.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-03-31 | −¥265m |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥18.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥18.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥11.5bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥225.4bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥225.1bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥300m |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥20.9bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥18.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥17.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥991m |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥1.4bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥108.6bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥108.0bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥609m |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥9.6bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥93.5bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥93.4bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥107m |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥16.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 779
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)財務戦略部長 松 尾 英 史 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00395 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 25030 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)キリンホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Kirin Holdings Company, Limited | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Current period end date | FilingDateInstant | 2024-03-31 | |
| Type of current period | FilingDateInstant | Q1 | |
| Current fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Comparative period end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所(プライム市場) | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)(注)１ | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式(単元株式数は100株) | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)同上 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |